Introduction to CereSpir
CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.
CereSpir is a private pharmaceutical company in New York, New York, U.S.A., founded by Daniel G. Chain, Ph.D. The Company assumed full rights to CSP-1103 in November 2013 and became the official sponsor of the IND in March 2014. CSP-1103 is a novel, first-in-class, small molecule microglial modulator. In a Phase 2 trial in people with Mild Cognitive Impairment (MCI), CSP-1103 was both well tolerated and appeared to both reduce brain inflammation and result in sustained cognition. MCI causes a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills. Most people with MCI progress to an AD diagnosis which currently affects more than 5 million Americans, 7 million Europeans and, in total, about 44 million people worldwide according to the most recent report by the Alzheimer’s Association.
Currently, In the United States, Medicare and Medicaid are expected to pay $150 billion annually for healthcare, long-term care and hospice for people with Alzheimer’s and other dementias and AD is one of the costliest chronic diseases to society. As the population ages, the social, medical and financial costs of this disease are anticipated to rise exponentially. Current treatments for AD are symptomatic and temporary.
There are no drugs approved which slow or halt the mental decline associated with this terrible disease. CereSpir is leading the way with a completely novel approach to AD by reducing inflammation and increasing clearance of tissue debris in the brain. The approach harnesses the innate immune system and targets aggregates of both beta amyloid (Aβ) and Tau protein that together cause irreversible damage to nerve cells and are the characteristic pathology of AD.